Jonathan Spicer, MD, PhD, Discusses Multidisciplinary Communication for Treating Resectable NSCLC With Neoadjuvant Immunotherapy

Video

CancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Jonathan Spicer, MD, PhD, of McGill University in Montreal, Canada, regarding multidisciplinary communication during the phase 3 CheckMate 816 trial (NCT02998528). As a leader, he spoke about how being forced to work with practitioners outside of his department helped the entire center become stronger.

CheckMate 816 focused on patients with resectable non–small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy), nivolumab plus chemotherapy, or chemotherapy alone with results supporting the use of nivolumab/chemotherapy as a potential neoadjuvant treatment in this setting.

Transcript:

When we first opened CheckMate 816, McGill University Health Center worked essentially on 2 main hospital sites, there’s Montreal General Hospital and the Royal Victoria Hospital. The Cancer Center is down at the Royal Victoria and Montreal General is where the surgery is done. We all work together but going through this trial was a real team building exercise. I think it brought all members of the team—medical oncologists, surgeons, pulmonologists—to get adequate staging biopsies [and] the interpretation of the resected specimen pathologically. It’s been a huge learning experience for pathologists and we’ve all had to communicate a lot about that and the care of these patients. I think we’ve all learned an enormous amount and it’s made us become a much more tightly knit team, which has been extremely positive. I’m grateful for that opportunity, because [as the] one leading this effort at McGill, it’s been really good for our team.

Reference

Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):8503. doi: 10.1200/JCO.2021.39.15_suppl.8503

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
4 experts in this video
4 experts in this video
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content